300158 振东制药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.779-0.843-0.76938.1434.729
总资产报酬率 ROA (%)0.665-0.691-0.61629.5813.610
投入资产回报率 ROIC (%)0.757-0.807-0.72834.6704.229

边际利润分析
销售毛利率 (%)50.86750.37549.31459.66762.234
营业利润率 (%)2.514-0.827-0.15961.2826.729
息税前利润/营业总收入 (%)2.247-1.3030.12661.4577.042
净利润/营业总收入 (%)1.611-1.320-1.52951.2325.231

收益指标分析
经营活动净收益/利润总额(%)-50.343401.7133,667.0272.70079.911
价值变动净收益/利润总额(%)72.042-119.491-1,250.83394.8034.332
营业外收支净额/利润总额(%)-10.21620.453-12.118-0.175-1.041

偿债能力分析
流动比率 (X)5.4014.8644.0384.6802.237
速动比率 (X)3.9133.5603.1504.1591.753
资产负债率 (%)13.63016.76920.26620.2010.259
带息债务/全部投入资本 (%)0.9861.2112.8934.0749.563
股东权益/带息债务 (%)9,906.5467,972.6533,282.5432,314.544903.707
股东权益/负债合计 (%)638.248499.702395.756396.256286.540
利息保障倍数 (X)-65.0704.9400.471218.05418.409

营运能力分析
应收账款周转天数 (天)77.65166.03076.49971.14582.872
存货周转天数 (天)276.557227.064191.597154.396139.506